ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Parse Biosciences Welcomes Admera Health as Newest Member of Certified Service Provider Network

Partnership Expands Access to Scalable, High-Quality Single Cell Analysis for Researchers

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, is pleased to announce that Admera Health, a premier provider of Next-Generation Sequencing services for researchers worldwide, has been certified as part of Parse’s Certified Service Provider (CSP) program. With this partnership, Admera joins the growing and trusted network of service labs offering Parse’s scalable single cell technology to researchers worldwide.

Introduced earlier this year, Parse’s CSP Program links researchers with reliable service providers for outsourcing single cell projects, ranging from small-scale exploratory studies to large, routine analyses. The program guarantees that these providers adhere to strict quality standards, offering scalable, high-performance solutions to drive scientific advancements.

“We are honored to partner with Parse Biosciences as a Certified Service Provider,” said Dr. Yun Zhao, CEO of Admera Health. “By integrating Parse’s innovative technology into our comprehensive suite of services, we are empowering researchers with scalable, high-quality single-cell solutions. It is a testament to Admera's commitment to providing exceptional service and driving scientific discovery.”

“From the beginning, our mission at Parse Biosciences has been to make scalable single cell solutions as accessible as possible,” said Alex Rosenberg, CEO and co-founder of Parse Biosciences. “Welcoming Admera Health into our network of trusted providers furthers this mission, empowering researchers to produce high-quality single cell data for any experiment with convenience and confidence.”

About Admera Health

Admera Health is a global provider of advanced genomic and bioinformatic support that leverages Next-Generation Sequencing expertise to serve researchers in academia, biotech, pharma, government, and animal health companies. Admera Health is located in New Jersey offering a comprehensive suite of services for all species such as genomics, transcriptomics, epigenomics, single-cell omics, spatial transcriptomics, bioinformatics, and tailored solutions. All samples are managed with exceptional attention and upheld to the highest quality standards, being processed in a CLIA/CLEP-certified and CAP-accredited environment.

Admera Health is at the forefront of research utilizing innovative next-generation sequencing technologies to provide comprehensive solutions. Our expert team employs state-of-the-art platforms and tools to deliver robust results through cutting-edge sequencing and bioinformatics.

For more information, please visit www.admerahealth.com.

About Parse Biosciences

Parse Biosciences is a global life sciences company dedicated to accelerating advancements in human health and scientific research. By empowering researchers to conduct single cell sequencing with unparalleled scale and simplicity, Parse’s innovative solutions are driving breakthroughs in cancer treatment, tissue repair, stem cell therapy, and more.

Built upon transformative technology developed at the University of Washington, Parse Biosciences has raised over $100 million and is used by over 2,000 labs worldwide. Its expanding product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and Trailmaker for advanced data analysis.

Headquartered in Seattle’s vibrant South Lake Union district, Parse Biosciences recently inaugurated a 34,000-square-foot facility featuring state-of-the-art laboratories to support its mission of advancing global research.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.